Filing Flows › Regen BioPharma (RGBP) › Q3 FY25
Regen BioPharma (RGBP) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 11, 2025
Regen BioPharma (RGBP) reported revenue of $59K for the third quarter fiscal 2025 (Q3 FY25), 0% from a year earlier and 0% from the quarter before. Operating margin was -69.0%, net loss $167K (283.2% of revenue).
Regen BioPharma, Q3 FY25: revenue $59K (0% year over year), operating margin -69.0%, net loss $167K, operating cash flow −$56K. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | 0% | 0% |
| Operating profit | −$41K | — | — |
| Net earnings | −$167K | — | — |
| Operating cash flow | −$56K | — | — |
What changed
Revenue was $59K in Q3 FY25, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $41K, an operating margin of -69.0%. Total costs fell 40% while revenue was flat. The fastest-growing cost line was General & admin (+86%). The quarter ended with a net loss of $167K, wider than the previous quarter's $19K loss. Net interest and other expense of $127K was the main reason.
Operating cash flow was −$56K. Working capital and other items added $111K.
Questions
What was Regen BioPharma's revenue in the third quarter fiscal 2025?
Regen BioPharma (RGBP) reported revenue of $59K for the third quarter fiscal 2025 (Q3 FY25), 0% from a year earlier and 0% from the quarter before.
Was Regen BioPharma profitable in the third quarter fiscal 2025?
Operating loss was $41K (-69.0% of revenue) and net loss $167K.
Source: Regen BioPharma 10-Q on SEC EDGAR.